Genetic mutations associated with acute myeloid leukemia can also be detected in age-related clonal hematopoiesis, making confident assignment of detected variants to malignancy challenging particularly in the post-treatment setting. This has implications for measurable residual disease monitoring, where the relationship between sequencing and flow cytometry is also imperfect. We show, using whole-genome-sequencing informed patient-personalized single-cell DNA and antibody-oligonucleotide sequencing, that it is possible to resolve immunophenotypic identity of clonal architecture.
Dillon, L.W., Ghannam, J., Nosiri, C., Gui, G., Goswami, M., Calvo, K.R., Lindblad, K.E., Oetjen, K.A., Wilkerson, M., Soltis, A.R., Sukumar, G., Dalgard, C.L., Thompson, J., Valdez, J., DeStefano, C.B., Lai, C., Sciambi, A., Durruthy-Durruthy, R., Llanso, A., Gulati, S., Wang, S., Ooi, A., Dagur, P.K., McCoy, J.P., Burr, P., Li, Y., Hourigan, C.S.
